Alexion Pharma's most recent trend suggests a bullish bias. One trading opportunity on Alexion Pharma is a Bull Put Spread using a strike $114.00 short put and a strike $109.00 long put offers a potential 11.11% return on risk over the next 29 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $114.00 by expiration. The full premium credit of $0.50 would be kept by the premium seller. The risk of $4.50 would be incurred if the stock dropped below the $109.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Alexion Pharma is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Alexion Pharma is bullish.
The RSI indicator is at 64.96 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Alexion Pharma
7 Hot Investing Bets to Make in Biotech
Tue, 19 Dec 2017 20:48:00 +0000
These favorite names in the volatile sector offer the potential for high rewards.
Why No Large-Cap Biotech Franchise Is Safe From Threats In 2018
Mon, 18 Dec 2017 21:26:11 +0000
No franchise is safe in 2018 among biotechs which are feeling pressure as the FDA speeds approvals for rival medicines.
ETFs with exposure to Alexion Pharmaceuticals, Inc. : December 12, 2017
Tue, 12 Dec 2017 17:42:15 +0000
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Alexion Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ALXN-US. Comparing the performance and risk of Alexion Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker … Read more
(Read more…)
Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at American Society of Hematology (ASH) Meeting
Mon, 11 Dec 2017 15:00:00 +0000
Alexion Pharmaceuticals, Inc. announced today the presentation of comprehensive dose-ranging data from two Phase 1b/2 studies of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal hemoglobinuria , a chronic, progressive, debilitating and potentially life-threatening ultra-rare blood disorder characterized by complement-mediated hemolysis.1,2 …
Analyst Recommendations for Alexion in December 2017
Mon, 11 Dec 2017 14:02:25 +0000
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”
Related Posts
Also on Market Tamer…
Follow Us on Facebook